<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356406</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-14-1630-DH-CTIL</org_study_id>
    <nct_id>NCT02356406</nct_id>
  </id_info>
  <brief_title>Celiac Plexus Radiosurgery for Pain Management</brief_title>
  <official_title>Celiac Plexus Radiosurgery for Pain Management in Advanced Cancer Patients - a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study evaluates celiac plexus radiosurgery for pain control in patients with
      upper abdominal malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims as primary objective to evaluate short and long term pain relief following
      the administration of radiosurgery to the celiac plexus in patients with upper abdominal
      cancer. As secondary objectives it will describe acute and late side effects and quality of
      life measures of patients undergoing the treatment.

      The study has a prospective, single arm design. It will be composed from an initial run-in
      safety assessment that will include 6 patients and then continue as a phase II trial. All
      eligible patients will receive the same protocol of celiac plexus radiosurgery and will be
      evaluated before, during and following this treatment.

      The treatment duration is one and a half weeks (5 fractions delivered every other weekday).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS) pain score difference from baseline</measure>
    <time_frame>3 weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale (NRS) pain score difference from baseline</measure>
    <time_frame>6 weeks and 3 months post treatment and subsequently every 3 months on average up to 1 year post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic use difference from baseline in oral morphin equivalents</measure>
    <time_frame>6 weeks and 3 months post treatment and subsequently every 3 months on average up to 1 year post treatment</time_frame>
    <description>Average analgesic consumption will be defined using daily oral morphine equivalents in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL difference from baseline</measure>
    <time_frame>6 weeks and 3 months post treatment and subsequently every 3 months on average up to 1 year post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of the procedure - measuring the frequency and severity of treatment side effects, mainly GI toxicities</measure>
    <time_frame>6 weeks and 3 months post treatment and subsequently every 3 months on average up to 1 year post treatment</time_frame>
    <description>The safety profile will focused on fatigue and expected GI (gastro-intestinal) toxicities as nausea, vomiting and diarrhea. Acute and late toxicity will be assessed using the NCI-CTCAE (common toxicity criteria for adverse events) version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Digestive System Neoplasms</condition>
  <arm_group>
    <arm_group_label>Celiac Plexus Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study has a prospective, single arm design. It will be composed from an initial run-in safety assessment that will include 6 patients and then continue as a phase II trial.
All eligible patients will receive the same protocol of celiac plexus radiosurgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Celiac Plexus Radiosurgery</intervention_name>
    <description>5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.
It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis.</description>
    <arm_group_label>Celiac Plexus Radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with upper abdominal cancer (pancreatic/gastric/colon/hepato-biliary cancer)
             with typical retroperitoneal pain syndrome (somatic pain that radiates from the upper
             abdomen to the back) thought to be secondary to celiac plexus involvement, directly or
             indirectly, and have high level of pain despite opioids usage (NRS &gt;4). Patients with
             other cancer types metastatic to the celiac lymph nodes will also be eligible

          -  Recent abdominal imaging (CT, PET or MRI) should be at most 2 months old.

          -  Prior chemotherapy or biological treatment is allowed, but any active oncological
             treatment should be stopped at least 1 week prior to radiation and renewed at least 1
             week following radiation. Following gemcitabine 2 weeks are required between final
             dose and commencement of radiation

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial

        Exclusion Criteria:

          -  Patients under 18 years of age

          -  Patients who are well balanced in terms of pain control

          -  Patients with life expectancy &lt;8 weeks

          -  Patients with ECOG (Eastern cooperative oncology group) performance status 4

          -  Any concurrent chemotherapy or biologic treatment is prohibited during 1 week before
             until 1 week following radiotherapy

          -  Special populations: pregnant women, prisoners, patients with major psychiatric
             illnesses

          -  Previous radiotherapy to upper abdomen

          -  Conditions associated with increased side effects to radiotherapy (IBD (inflammatory
             bowel disease) for example)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hausner, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hausner, M.D</last_name>
    <phone>972-35302542</phone>
    <email>david.hausner@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaacov R Lawrence, MBBS MA MRCP</last_name>
    <phone>972-35302290</phone>
    <email>Yaacov.Lawrence@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hausner, M.D</last_name>
      <phone>972-35302542</phone>
      <email>David.Hausner@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Yaacov R Lawrence, MBBS MA MRCP</last_name>
      <phone>972-35302290</phone>
      <email>Yaacov.Lawrence@sheba.health.gov.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Levy MJ, Wiersema MJ. EUS-guided celiac plexus neurolysis and celiac plexus block. Gastrointest Endosc. 2003 Jun;57(7):923-30. Review.</citation>
    <PMID>12776048</PMID>
  </reference>
  <reference>
    <citation>Kambadakone A, Thabet A, Gervais DA, Mueller PR, Arellano RS. CT-guided celiac plexus neurolysis: a review of anatomy, indications, technique, and tips for successful treatment. Radiographics. 2011 Oct;31(6):1599-621. doi: 10.1148/rg.316115526. Review.</citation>
    <PMID>21997984</PMID>
  </reference>
  <reference>
    <citation>Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M, BÃ¼chler MW. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol. 1999 Aug;17(8):2419-28.</citation>
    <PMID>10561305</PMID>
  </reference>
  <reference>
    <citation>Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, Mantilla CB, Warner DO. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA. 2004 Mar 3;291(9):1092-9.</citation>
    <PMID>14996778</PMID>
  </reference>
  <reference>
    <citation>Smigielski J, Piskorz L, Wawrzycki M, Kutwin L, Misiak P, Brocki M. Assessment of quality of life in patients with non-operated pancreatic cancer after videothoracoscopic splanchnicectomy. Wideochir Inne Tech Maloinwazyjne. 2011 Sep;6(3):132-7. doi: 10.5114/wiitm.2011.24690. Epub 2011 Sep 30.</citation>
    <PMID>23255971</PMID>
  </reference>
  <reference>
    <citation>Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinowitz S. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg. 2010 Oct;14(10):1547-59. doi: 10.1007/s11605-010-1323-7. Epub 2010 Sep 14.</citation>
    <PMID>20839073</PMID>
  </reference>
  <reference>
    <citation>Rwigema JC, Parikh SD, Heron DE, Howell M, Zeh H, Moser AJ, Bahary N, Quinn A, Burton SA. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011 Feb;34(1):63-9. doi: 10.1097/COC.0b013e3181d270b4.</citation>
    <PMID>20308870</PMID>
  </reference>
  <reference>
    <citation>Macchia G, Morganti AG, Cilla S, Ippolito E, Massaccesi M, Picardi V, Mattiucci GC, Bonomo P, Tambaro R, Pacelli F, Piermattei A, De Spirito M, Valentini V, Cellini N, Deodato F. Quality of life and toxicity of stereotactic radiotherapy in pancreatic tumors: a case series. Cancer Invest. 2012 Feb;30(2):149-55. doi: 10.3109/07357907.2011.640649.</citation>
    <PMID>22250589</PMID>
  </reference>
  <reference>
    <citation>Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):516-22. doi: 10.1016/j.ijrobp.2013.02.022. Epub 2013 Apr 5.</citation>
    <PMID>23562768</PMID>
  </reference>
  <reference>
    <citation>Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149-58.</citation>
    <PMID>11690728</PMID>
  </reference>
  <reference>
    <citation>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-21. Epub 2007 Dec 11.</citation>
    <PMID>18055266</PMID>
  </reference>
  <reference>
    <citation>Iwata K, Yasuda I, Enya M, Mukai T, Nakashima M, Doi S, Iwashita T, Tomita E, Moriwaki H. Predictive factors for pain relief after endoscopic ultrasound-guided celiac plexus neurolysis. Dig Endosc. 2011 Apr;23(2):140-5. doi: 10.1111/j.1443-1661.2010.01046.x. Epub 2010 Dec 7.</citation>
    <PMID>21429019</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>February 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2015</study_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>David Hausner M.D</investigator_full_name>
    <investigator_title>palliative care physician</investigator_title>
  </responsible_party>
  <keyword>Radiosurgery</keyword>
  <keyword>Celiac Plexus</keyword>
  <keyword>Pain</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

